Latest filing published 03 Jul 2017 for Tvardi Therapeutics, Inc., €5.2M.
Filing timeline
BuySaleInsider track record
Dean Slagel: trading record in brief
All filings by Dean Slagel on record concern Tvardi Therapeutics, Inc. Between 5 February 2014 and 29 June 2017, the trades on record add up to 11 filings.
No open-market purchase appears, only 9 sales worth €8.7M. In 2017 alone, the filings show no purchases and 2 sales.
The latest filing, published on 3 July 2017, reports an open-market sale of €5.2M in Tvardi Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Dean Slagel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 229,138 shares@ US$25.81Common StockSEC:0001209191-17-042886:0
- 20,862 shares@ US$26.58Common StockSEC:0001209191-17-042886:1
- 12,776 shares@ US$17.0014.4% of flowCommon StockSEC:0001209191-16-088822:0
- 31,224 shares@ US$17.0135.6% of flowCommon StockSEC:0001209191-16-088822:1
- 32,266 shares@ US$10.00Common StockSEC:0001209191-15-044516:2
- 73,600 shares@ US$10.00Common StockSEC:0001209191-15-044516:0
- 82,945 shares@ US$10.04Common StockSEC:0001209191-15-044516:1
- 80,000 shares0Common StockSEC:0001209191-14-007642:0
- 84,149 shares0Common StockSEC:0001209191-14-007642:1
9 of 9 declarations